Dr. Hameed is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
350 Parnassus Ave
Ste 300
San Francisco, CA 94117Phone+1 415-353-1117Fax+1 415-353-2407
Summary
- I am a board certified hepatologist treating patients with liver disease at UCSF Medical Center.
Education & Training
- University of California (San Francisco)Fellowship, Transplant Hepatology, 2009 - 2010
- University of MinnesotaFellowship, Gastroenterology, 2006 - 2009
- University of MinnesotaResidency, Internal Medicine, 2003 - 2006
- Dow University of Health SciencesClass of 2000
Certifications & Licensure
- CA State Medical License 2009 - 2025
- NV State Medical License 2012 - 2019
- MN State Medical License 2006 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Transplant Hepatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis Start of enrollment: 2021 May 15
Roles: Principal Investigator, Contact
- Liver Cirrhosis Network Cohort Study Start of enrollment: 2022 Nov 14
Roles: Contact
- Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States Start of enrollment: 2023 Oct 11
Roles: Contact
Publications & Presentations
PubMed
- 1590 citationsFarnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialBrent A. Neuschwander-Tetri, Rohit Loomba, Arun J. Sanyal, Joel E. Lavine, Mark L. Van Natta
Lancet. 2015-03-14 - 176 citationsThe Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Stephen H. Caldwell, Mitchell L. Shiffman
Hepatology. 2019-09-01 - 297 citationsDownstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteriaFrancis Y. Yao, Neil Mehta, Jennifer A. Flemming, Jennifer L. Dodge, Bilal Hameed
Hepatology. 2015-06-01
Press Mentions
- CloudMedx Working with UCSF to Deploy AI Tools to Support the Management of Liver Cancer Patients Awaiting Liver TransplantAugust 3rd, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: